As of 2026-04-22, the Intrinsic Value of Denali Therapeutics Inc (DNLI) is -16.16 USD. This DNLI valuation is based on the model Peter Lynch Fair Value. With the current market price of 20.13 USD, the upside of Denali Therapeutics Inc is -180.27%.
Based on its market price of 20.13 USD and our intrinsic valuation, Denali Therapeutics Inc (DNLI) is overvalued by 180.27%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -16.16 - -16.16 | -16.16 | -180.27% |
| P/E | (72.07) - (80.60) | (74.01) | -467.7% |
| DDM - Stable | (36.74) - (189.49) | (113.12) | -661.9% |
| DDM - Multi | (1.40) - (5.60) | (2.24) | -111.1% |
| Market Cap (mil) | 3,192.42 |
| Beta | 1.67 |
| Outstanding shares (mil) | 158.59 |
| Enterprise Value (mil) | 2,992.71 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.85% |
| Cost of Debt | 5.00% |
| WACC | 7.84% |